China’s health regulator has approved AstraZeneca’s Tagrisso (osimertinib) as an adjuvant treatment for patients with a form of early-stage, EGFR-mutated nonsmall-cell lung cancer.

The approval was supported by results form a phase 3 trial in which the drug reduced the risk of disease recurrence or death by 80 percent, the drugmaker said.

Tagrisso has been approved for treating early-stage lung cancer in more than a dozen countries, including the U.S., and is currently being reviewed by other global regulators.